Contrarily, novel ACVR2 ligand traps, Luspatercept and Sotatercept, are showing early promise in clinical trials in patients with myelodysplastic syndromes (NCT02631070) and pulmonary arterial hypertension (NCT03496207), yet whether either of these drugs would be beneficial in combatting the musculoskeletal complications resulting from CRC‐induced cachexia will require further testing. The gene discussed is ACVR2A; the disease is pulmonary arterial hypertension.